Key Highlights
- Shares are trading up about 47.53% today, among the session's largest biotech gainers.
- Phase 2 results showed a statistically significant impact on complete hive resolution.
- High baseline IgE patients saw a 78% complete hive resolution rate versus 0% for placebo.
- The FDA has cleared an IND application to advance the candidate into food allergy.
- A separate autoimmune candidate began first-in-human dosing this quarter.
Cue Biopharma (NASDAQ:CUE) shares are surging today after the company reported positive Phase 2 topline results for its lead candidate, CUE-221, in chronic spontaneous urticaria, alongside third-quarter financial results. Cue Biopharma is a clinical-stage biopharmaceutical company developing therapies for immune-mediated diseases, with CUE-221 designed as a dual-mechanism anti-IgE antibody.
Phase 2 Results Show Differentiated Clinical Benefit
The study demonstrated a highly statistically significant dose-responsive impact on complete hives resolution, the trial's primary endpoint, along with significant improvement on a key secondary measure of complete response. In a prespecified subgroup of patients with high baseline IgE levels, 78% achieved complete hive resolution at the higher dose compared with 0% on placebo.
Food Allergy Program Advances With FDA Clearance
The company said the clinical and pharmacological findings support advancing CUE-221 into its food allergy program, and the FDA has cleared an investigational new drug application to do so. Management believes the candidate's dual mechanism, which both neutralizes existing IgE and prevents synthesis of new IgE, could expand the population of patients eligible for anti-IgE therapy.
CUE-401 Autoimmune Candidate Begins Dosing
Separately, the company initiated first-in-human dosing of CUE-401, its lead autoimmune candidate designed to regulate inflammation and promote immune tolerance, marking a key 2026 milestone as the company's first autoimmune therapeutic to enter clinical testing.
Financial Results Reflect Higher Clinical Investment
Third-quarter Revenue was $0.1 million, down from $2.1 million a year earlier, while Research and Development expenses rose to $17.0 million from $4.8 million on higher clinical trial costs. Net loss widened to $50.0 million from $7.4 million, with the company holding $57.9 million in cash as of September 30.






Please wait processing your request...